Table 3.
Summarized results of the qualitative synthesis of 101 treatment arms in 65 studies.
| Concentration-efficacy | Concentration-side effects | |||||
|---|---|---|---|---|---|---|
| Substance class (N studies, N treatment arms) | Positive C-E relationship |
Negative C-E relationship |
No C-E relationship |
Positive C-SE relationship |
Negative C-SE relationship | No C-SE relationship |
| TCA (47, 57) | 19 | 5 | 33 | 9 | – | 14 |
| SSRI (21, 27) | 5 | 2 | 20 | 5 | – | 9 |
| Tetra-CA (9, 9) | 1 | 1 | 7 | 1 | – | 4 |
| SSNRI (6, 6) | 1 | – | 5 | 2 | – | – |
| MAO-Inhibitors (1, 1) | – | – | 1 | – | – | – |
| SNDRI (1, 1) | – | – | 1 | – | – | – |
C-E, Concentration-efficacy; C-SE, Concentration-side effects; SSNRI, Venlafaxine; MAO-Inhibitors, Moclobemide; SNDRI, Bupropion.